Key result
E-iliac branched device achieves ~97% technical success and maintains mid-term patency in aortoiliac aneurysms.
Why the study?
Mid-term outcomes of the E-iliac branched device in treating aortoiliac aneurysms were not well established.
Does the E-iliac branched device provide safe and effective mid-term outcomes in patients with aortoiliac aneurysms?
Cohort (n=38)
No
Does the E-iliac branched device provide safe and effective mid-term outcomes in patients with aortoiliac aneurysms?
The E-iliac branched device demonstrates high technical success and excellent mid-term patency for the treatment of aortoiliac aneurysms.
E-iliac device shows high mid-term patency and low reintervention in this cohort; leaves open need for prospective trials to guide wider use.
The aim was to assess the mid-term results of the E-iliac branched device. Baseline and follow-up data of this monocentric retrospective cohort study including all consecutive patients with aortoiliac aneurysms treated with iliac branched devices between 2016 and 2023 were extracted from the hospital records. Preoperative and follow-up CT scans were analyzed regarding endoleaks, migration, aneurysm sac remodeling, and device patency. Overall, 50 devices were implanted in 38 patients with a median age of 69 (IQR 62-78) years, and 1.6 bridging stent grafts per vessel were implanted through transfemoral (22/50; 44%) or upper extremity access (28/50; 56%). Primary technical success and assisted technical success were 97% (37/38) and 100% (38/38), respectively. No migration, no type I or III endoleaks, no stroke, colonic ischemia, aneurysm rupture, or conversion during the early and mid-term follow-ups (11 months, IQR 5-26) were observed. Aneurysm sac enlargement or shrinkage was observed in 0% (0/38) and 16% (6/38) patients, respectively. E-iliac-related re-interventions were seen only during the early follow-up: two thrombectomies with bare-metal stent relining after thrombosis of the iliac limb. Bridging stent graft and E-iliac patency during the mid-term follow-up were 100%. E-iliac showed encouraging mid-term results in the treatment of aortoiliac aneurysms with high technical success and a low re-intervention rate.
No takes yet. Share an insight, caveat, or question.
Bonorden et al. (2023) conducted a cohort in Abdominal Aortoiliac Aneurysms (n=38). E-iliac branched device was evaluated on Primary technical success. The E-iliac branched device achieved a 97% primary technical success rate and 100% mid-term patency with no type I or III endoleaks in patients with aortoiliac aneurysms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: